• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Inhibikase Therapeutics Inc.

    10/22/24 4:15:58 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IKT alert in real time by email
    SC 13G 1 d829059dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Inhibikase Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    45719W205

    (CUSIP Number)

    October 21, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 45719W205

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Advisors LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     6,799,944

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     6,799,944

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,799,944

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.99%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IA


    CUSIP No. 45719W205

     

     1   

     NAMES OF REPORTING PERSONS

     

     Joseph Edelman

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     6,799,944

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     6,799,944

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,799,944

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.99%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN


    CUSIP No. 45719W205

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Life Sciences Master Fund, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     6,799,944

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     6,799,944

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,799,944

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.99%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     CO


    Item 1(a).    Name of Issuer:
       Inhibikase Therapeutics, Inc. (the “Issuer”)
    Item 1(b).    Address of Issuer’s Principal Executive Offices:
       3350 Riverwood Parkway SE, Suite 1900
       Atlanta, GA 30339
    Item 2(a).    Names of Persons Filing:
       The names of the persons filing this report (collectively, the “Reporting Persons”) are:
       Perceptive Advisors LLC (“Perceptive Advisors”)
       Joseph Edelman (“Mr. Edelman”)
       Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
    Item 2(b).    Address of Principal Business Office or, if None, Residence:
       The address of the principal business office of each of the Reporting Persons is:
       51 Astor Place, 10th Floor
       New York, NY 10003
    Item 2(c).    Citizenship:
       Perceptive Advisors is a Delaware limited liability company
       Mr. Edelman is a United States citizen
       The Master Fund is a Cayman Islands corporation
    Item 2(d).    Title of Class of Securities:
       Common Stock, par value $0.001 per share (“Common Stock”)
    Item 2(e).    CUSIP Number:
       45719W205
    Item 3.    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       Not applicable.
    Item 4.    Ownership.
       The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G and assumes the exercise of pre-funded warrants (the “Pre-Funded Warrants”) to purchase 874,944 shares of the Issuer’s Common Stock. The ownership percentages reported are based on (i) 67,192,570 shares of Common Stock outstanding as of October 21, 2024, as reported by the Issuer to the Reporting Persons (giving effect to 58,310,000 shares of Common Stock sold by the Issuer pursuant to a securities purchase agreement, dated October 9, 2024, as reported by the Issuer in its Current Report on Form 8-K filed on October 10, 2024), and (ii) assumes the exercise by the Reporting Persons of Pre-Funded Warrants to purchase 874,944 shares of the Company’s Common Stock.


       Neither Perceptive Advisors nor Mr. Edelman directly holds any Common Stock. The Master Fund directly holds 5,925,000 shares of Common Stock and Pre-Funded Warrants to purchase shares of the Issuer’s Common Stock. The Pre-Funded Warrants provide that the holder of such warrants will not have the right to exercise any portion of such warrants if such holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. As a result of this restriction, only a portion of the Pre-Funded Warrants acquired by the Reporting Persons is exercisable. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.
    Item 5.    Ownership of Five Percent or Less of a Class.
       If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person.
       Not applicable.
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       Not applicable.
    Item 8.    Identification and Classification of Members of the Group.
       Not applicable.
    Item 9.    Notice of Dissolution of Group.
       Not applicable.
    Item 10.    Certification.
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: October 22, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:   /s/ Joseph Edelman
     

    Name:   Joseph Edelman

     

    Title:   Managing Member

     

    /s/ Joseph Edelman

    JOSEPH EDELMAN

     

    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:   Perceptive Advisors LLC
    By:   /s/ Joseph Edelman
     

    Name:   Joseph Edelman

     

    Title:   Managing Member

     

    Get the next $IKT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IKT

    DatePrice TargetRatingAnalyst
    2/12/2025Buy → Neutral
    H.C. Wainwright
    7/15/2021$12.00Buy
    JonesTrading
    More analyst ratings

    $IKT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

    BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension ("PAH"), today announced the appointment of veteran biopharma executive Timothy Pigot as the Company's Chief Commercial and Strategy Officer. "Tim Pigot is an accomplished pharma industry business leader and a deeply respected expert in the PAH market landscape, and we are delighted to welcome him to the Inhibikase team," said Mark Iwicki, Chief Executive Officer of Inhibikase. "As we advance IKT-001 toward a late-stage clinical trial in PAH, Tim'

    8/19/25 8:00:00 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

    BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments. "During our second quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH," said Mark Iwicki, Chief Executive Officer of Inhibikase. "We have now finalized our study protocol, and we expect to initiate our Phase 2b clinical study of IKT-001, o

    8/14/25 4:50:16 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

    BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ("PAH"), today reported financial results for the quarter ended March 31, 2025 and highlighted recent developments. "During our first quarter of 2025, we continued to build out our senior leadership team and key infrastructure areas to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH," said Mark Iwicki, Chief Executive Officer of Inhibikase. "With our core team now in place, and with ongoing refinin

    5/14/25 4:05:00 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.

    SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)

    8/14/25 8:27:41 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Inhibikase Therapeutics Inc.

    10-Q - Inhibikase Therapeutics, Inc. (0001750149) (Filer)

    8/14/25 5:06:24 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibikase Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)

    8/14/25 4:56:14 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: New insider Cabell Christopher claimed ownership of 1,014,846 shares (SEC Form 3)

    3/A - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

    8/28/25 7:52:09 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: New insider Aurentz Vincent claimed ownership of 765,895 shares (SEC Form 3)

    3/A - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

    8/28/25 7:50:18 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Munshi Amit was granted 57,265 shares (SEC Form 4)

    4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

    8/28/25 7:48:20 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Inhibikase Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Inhibikase Therapeutics from Buy to Neutral

    2/12/25 7:05:10 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    JonesTrading initiated coverage on Inhibikase Therapeutics with a new price target

    JonesTrading initiated coverage of Inhibikase Therapeutics with a rating of Buy and set a new price target of $12.00

    7/15/21 9:29:48 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bellini Roberto bought $2,000,200 worth of shares (1,460,000 units at $1.37) (SEC Form 4)

    4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

    10/23/24 7:53:27 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kush Arvind bought $198,650 worth of shares (145,000 units at $1.37) (SEC Form 4)

    4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

    10/23/24 7:49:49 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Munshi Amit bought $500,050 worth of shares (365,000 units at $1.37) (SEC Form 4)

    4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)

    10/23/24 7:43:35 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKT
    Leadership Updates

    Live Leadership Updates

    View All

    Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

    BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension ("PAH"), today announced the appointment of veteran biopharma executive Timothy Pigot as the Company's Chief Commercial and Strategy Officer. "Tim Pigot is an accomplished pharma industry business leader and a deeply respected expert in the PAH market landscape, and we are delighted to welcome him to the Inhibikase team," said Mark Iwicki, Chief Executive Officer of Inhibikase. "As we advance IKT-001 toward a late-stage clinical trial in PAH, Tim'

    8/19/25 8:00:00 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

    BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ("PAH"), today announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025. "David has extensive experience in financial strategy and corporate governance, as well as an established reputation within the life sciences capital markets sector, and we are thrilled to welcome him as our new Chief Financial Officer," said Mark Iwicki, Chief Executive Officer of Inhibikase Therapeutics. "We look for

    4/14/25 8:00:00 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibikase Announces Expansion of Senior Leadership Team

    --- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Directors --- BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), today announced the appointment of two pharma industry executives with deep experience in pulmonary arterial hypertension ("PAH") to its senior leadership team. Chris Cabell, M.D., former Chief Medical Officer of Arena Pharmaceuticals and Chief Executive Officer of CorHepta Pharmaceuticals, Inc. ("CorHepta") has been appointed as President and Head of Research & D

    2/24/25 8:00:00 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IKT
    Financials

    Live finance-specific insights

    View All

    $IKT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

    BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 15, 2024, to provide a corporate update and review the financial results. The

    8/7/24 8:00:08 AM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

    BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the first quarter ended March 31, 2024 and highlighted recent developments. "2024 is shaping up to be a year of clinical and regulatory execution as we advance our core programs towards important inflection points," said Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase. "The Phase 2 201 t

    5/15/24 8:00:00 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

    BOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent developments. "2023 was a year of clinical execution across our pipeline, culminating in the recent pre-NDA meeting with the FDA for IkT-001Pro and robust enrollment of untreated Parkinson's patients in our 201 Trial evaluating Risvod

    3/27/24 4:15:20 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Inhibikase Therapeutics Inc.

    SC 13G - Inhibikase Therapeutics, Inc. (0001750149) (Subject)

    11/14/24 3:31:08 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Inhibikase Therapeutics Inc.

    SC 13G - Inhibikase Therapeutics, Inc. (0001750149) (Subject)

    10/28/24 5:26:55 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Inhibikase Therapeutics Inc.

    SC 13G - Inhibikase Therapeutics, Inc. (0001750149) (Subject)

    10/28/24 4:00:29 PM ET
    $IKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care